




Mouse Anti-Feline CD5

Cat. No.	Format	Size
8100-01	Purified (UNLB)	0.5 mg
8100-02	Fluorescein (FITC)	0.5 mg
8100-08	Biotin (BIOT)	0.5 mg
8100-09	R-phycoerythrin (PE)	0.1 mg



Feline peripheral blood lymphocytes were stained with Mouse Anti-Feline CD5-PE (SB Cat. No. 8100-09) and Mouse Anti-Feline CD8-FITC (SB Cat. No. 8120-02).

Overview

Clone	f43
Isotype	Mouse IgG ₁ κ
Immunogen	Feline T cells
Specificity	Feline/Lion CD5; Mr 72 kDa
Alternate Name(s)	fCD5, Pan T cell

Description

Feline CD5, a member of the scavenger receptor family of cell surface receptors, is a type I transmembrane glycoprotein that is expressed on most thymocytes and mature T lymphocytes. CD5 is thought to function in both cell-cell recognition and signal transduction. The monoclonal antibody f43 is useful as a pan T cell marker.

Applications

FC – Quality tested ^{1,4-19}
 IHC-FS – Reported in literature ²
 IP – Reported in literature ¹
 ELISA – Reported in literature ³

Working Dilutions

Flow Cytometry	FITC and BIOT conjugates	≤ 1 μg/10 ⁶ cells
	PE conjugate	≤ 0.2 μg/10 ⁶ cells
For flow cytometry, the suggested use of these reagents is in a final volume of 100 μL		

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Ackley CD, Cooper MD. Characterization of a feline T-cell-specific monoclonal antibody reactive with a CD5-like molecule. *Am J Vet Res.* 1992;53:446-71. (Immunogen, FC, IP)
2. Fox JG, Perkins S, Yan L, Shen Z, Attardo L, Pappo J. Local immune response in *Helicobacter pylori*-infected cats and identification of *H. pylori* in saliva, gastric fluid and faeces. *Immunology.* 1996;88:400-6. (IHC-FS)
3. Bishop SA, Stokes CR, Gruffydd-Jones TJ, Whiting CV, Humphries JE, Osborne R, et al. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. *Vaccine.* 1996;14:1243-50. (ELISA)
4. Shimojima M, Miyazawa T, Kohmoto M, Ikeda Y, Nishimura Y, Maeda K, et al. Expansion of CD8 α β - cells in cats infected with feline immunodeficiency virus. *J Gen Virol.* 1998;79:91-4. (FC)
5. Phipps AJ, Hayes KA, Buck WR, Podell M, Mathes LE. Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. *J Acquir Immune Defic Syndr.* 2000;23:8-16. (FC)
6. Hokanson RM, TerWee J, Choi I, Coates J, Dean H, Reddy DN, et al. Dose response studies of acute feline immunodeficiency virus PPR strain infection in cats. *Vet Microbiol.* 2000;76:311-27. (FC)
7. Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. *J Infect Dis.* 2000;181:576-86. (FC)
8. Shimojima M, Nishimura Y, Miyazawa T, Kato K, Nakamura K, Izumiya Y, et al. A feline CD2 homologue interacts with human red blood cells. *Immunology.* 2002;105:360-6. (FC)
9. Hohdatsu T, Yamazaki A, Yamada M, Kusuhara H, Kaneshima T, Koyama H. Ability of CD8⁺ T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4⁺ T cell counts and plasma viremia. *Microbiol Immunol.* 2003;47:765-73. (FC)
10. Howard KE, Fisher IL, Dean GA, Burkhard MJ. Methodology for isolation and phenotypic characterization of feline small intestinal leukocytes. *J Immunol Methods.* 2005;302:36-53. (FC)
11. Brennan G, Podell MD, Wack R, Kraft S, Troyer JL, Bielefeldt-Ohmann H, et al. Neurologic disease in captive lions (*Panthera leo*) with low-titer lion lentivirus infection. *J Clin Microbiol.* 2006;44:4345-52. (FC, Lion Reactivity)
12. Dean GA, LaVoy A, Yearley J, Stanton C. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats. *J Infect Dis.* 2006;193:1520-7. (FC)
13. Howard KE, Burkhard MJ. FIV infection induces unique changes in phenotype and cellularity in the medial iliac lymph node and intestinal IEL. *AIDS Res Hum Retroviruses.* 2007;23:720-8. (FC)
14. Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, et al. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. *Virus Res.* 2007;127:9-16. (FC)
15. Mikkelsen SR, Reckling SK, Egan EA, Dean GA. In vivo depletion of CD4⁺CD25^{hi} regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus. *Virology.* 2010;403:163-72. (FC)
16. Thompson J, MacMillan M, Boegler K, Wood C, Elder JH. Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. *PLoS One.* 2011;6(8):e24020. (FC)
17. Novacco M, Boretti FS, Franchini M, Riond B, Meli ML, Hofmann-Lehmann R. Protection from reinfection in "Candidatus *Mycoplasma turicensis*"-infected cats and characterization of the immune response. *Vet Res.* 2012;43:82. (FC)
18. Trzil JE, Masseau I, Webb TL, Chang C, Dodam JR, Cohn LA, et al. Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma. *Clin Exp Allergy.* 2014;44:1546-57. (FC)
19. Hicks CA, Willi B, Riond B, Novacco M, Meli ML, Stokes CR, et al. Protective Immunity against Infection with *Mycoplasma haemofelis*. *Clin Vaccine Immunol.* 2015;22:108-18. (FC)